Keywords: AB; alpha-adrenergic blocker; BPH; benign prostatic hyperplasia; 5-ARI; 5-alpha reductase inhibitor; LUTS; lower urinary tract symptom; PCPT; Prostate Cancer Prevention Trial; PSA; prostate specific antigen; SHR; subdistribution hazard ratio;